Eckert & Ziegler has announced a strategic turnaround in drug development. This could pay off for shareholders.
A column by Holger Steffen, investment expert and advisor for the Value Stars Germany Index.
The nine-month figures for our Eckert & Ziegler portfolio value were in line with expectations. Sales rose by almost 11% to 183.9 million euros, while the net result fell by a good 6% to 20.3 million euros. Pentixafarm’s active ingredient development was a stressor. This will be done through a spin-off in the future […]
